⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EWTX News
Edgewise Therapeutics, Inc. Common Stock
Form 8-K/A
sec.gov
EWTX
Form 8-K
sec.gov
EWTX
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
prnewswire.com
EWTX
Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics
prnewswire.com
EWTX
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
prnewswire.com
EWTX
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
prnewswire.com
EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com
EWTX
Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
globenewswire.com
NTHI
CRVO
EWTX
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
prnewswire.com
EWTX
Form 8-K
sec.gov
EWTX